Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial
Summary Background The DiRECT trial assessed remission of type 2 diabetes during a
primary care-led weight-management programme. At 1 year, 68 (46%) of 149 intervention …
primary care-led weight-management programme. At 1 year, 68 (46%) of 149 intervention …
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year …
Background Men who are overweight or obese frequently have low serum testosterone
concentrations, which are associated with increased risk of type 2 diabetes. We aimed to …
concentrations, which are associated with increased risk of type 2 diabetes. We aimed to …
[PDF][PDF] Care in diabetes—2022
D Care - Diabetes care, 2022 - healthy.arkansas.gov
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …
the ADA's current clinical practice recommendations and is intended to provide the …
Metabolic syndrome—A new definition and management guidelines
P Dobrowolski, A Prejbisz, A Kuryłowicz… - Arterial …, 2022 - journals.viamedica.pl
The joint position paper by Polish Society of Hypertension, Polish Society for the Treatment
of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of …
of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of …
[HTML][HTML] Safety of semaglutide
MM Smits, DH Van Raalte - Frontiers in endocrinology, 2021 - frontiersin.org
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …
approved agent of this drug class, and the only GLP-1RA currently available as both …
[HTML][HTML] Cardiovascular risk and obesity
C Cercato, FA Fonseca - Diabetology & metabolic syndrome, 2019 - Springer
Background This is an overview of the mechanisms of obesity and its relation to
cardiovascular risks, describing the available treatment options to manage this condition …
cardiovascular risks, describing the available treatment options to manage this condition …
Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study
Q Gong, P Zhang, J Wang, J Ma, Y An… - The lancet Diabetes & …, 2019 - thelancet.com
Background Lifestyle interventions can delay the onset of type 2 diabetes in people with
impaired glucose tolerance, but whether this leads subsequently to fewer complications or to …
impaired glucose tolerance, but whether this leads subsequently to fewer complications or to …
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active …
Background Obesity is a major public health issue, and new pharmaceuticals for weight
management are needed. Therefore, we evaluated the efficacy and safety of the glucagon …
management are needed. Therefore, we evaluated the efficacy and safety of the glucagon …
[HTML][HTML] GLP− 1 receptor agonists for the treatment of obesity: Role as a promising approach
JY Wang, QW Wang, XY Yang, W Yang… - Frontiers in …, 2023 - frontiersin.org
Obesity is a complex disease characterized by excessive fat accumulation which is caused
by genetic, environmental and other factors. In recent years, there has been an increase in …
by genetic, environmental and other factors. In recent years, there has been an increase in …